RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
RxSight (RXST) Gets a Buy From Morgan Stanley
RxSight Price Target Raised to $73.00/Share From $72.00 by BTIG
RxSight Is Maintained at Buy by BTIG
BTIG Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $73
Express News | Rxsight Inc : Btig Raises Target Price to $73 From $72
Institutional Investors May Overlook RxSight, Inc.'s (NASDAQ:RXST) Recent US$280m Market Cap Drop as Long-term Gains Remain Positive
RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
RxSight Down Over 17%, on Pace for Record Percent Decrease -- Data Talk
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Express News | RxSight Shares Are Trading Lower After Stifel Maintained a Buy Rating on the Stock and Lowered Its Price Target From $75 to $70
Stifel Maintains Buy on RxSight, Lowers Price Target to $70
RxSight Analyst Ratings
Stifel Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $70
Express News | Rxsight Inc : Stifel Cuts Target Price to $70 From $75
RxSight(RXST.US) Officer Sells US$1.08 Million in Common Stock
Form 144 | RxSight(RXST.US) Officer Proposes to Sell 586.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $RxSight(RXST.US)$ Officer SHELLEY B THUNEN intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $586.06K. SHELLEY B